Staying Connected To The Navigation Community

← Back to Issue


Uncategorized

Staying Connected To The Navigation Community

Lillie D. Shockney, RN, BS, MAS, ONN-CG 

Lillie D. Shockney, RN, BS, MAS

Dear Colleague,

On behalf of our editorial board, it is my pleasure to present this issue of Journal of Oncology Navigation & Survivorship (JONS) to you, our reading community.

In each issue, we strive to present articles that directly impact your practice and enable you to provide better care. As healthcare providers, however, we are faced with an abundance of information critical to our professional performance—much more information than can fit into the pages of a journal. Internet connectivity allows a convenient method to access the information we need immediately as well as provides a forum for the exchange of ideas. Yet, there is an irreplaceable connection we have to the printed word—the unparalleled experience of holding a journal in our hands and feeling a connection with the author of that work. And finally, there is the ultimate experience and personal satisfaction in meeting with colleagues to share ideas.

It is our goal to provide all of these avenues to our community of oncology navigators. We recognize that navigators are unique in that our patients require not only our medical skill and knowledge but also our nurturing and encouragement. And so, in support of all you do, and to promote our connectedness with each other, we offer the information you need in print, online, and at our annual conference.

Please accept our invitation to connect with us at www.AONNonline.org and at our Second Annual Navigation and Survivorship Conference, September 16-18, in San Antonio, Texas. It is my hope to see you there!

With best regards,

Lillie D. Shockney,

RN, BS, MAS

Editor-in-Chief

Related Articles
In the News - December 11, 2015

FDA Approves Empliciti, a New Immune-Stimulating Therapy to Treat Multiple Myeloma

Today the U.S. Food and Drug Administration granted approval for Empliciti (elotuzumab) in combination with two other therapies to treat people with multiple myeloma who have received one to three [ Read More ]

Breast Cancer, Web Exclusive - April 7, 2018

Breaking News: Sellas Announces Promising Data on NeuVax in Combination with Herceptin in HER2 1+/2+ Breast Cancer

This week Sellas Life Sciences Group announced data from a study of NeuVax (nelipepimut-S) in combination with Herceptin (trastuzumab) in patients with HER2 1+/2+ breast cancer. All node-negative (N0) patients [ Read More ]